Grünwald V., McKay R.R., Krajewski K.M., Kalanovic D., Lin X., Perkins J.J., Simantov R., Choueiri T.K.
European Urology 2015 67:5 (952-958)
Background Response remains an important endpoint in clinical cancer trials. However, the prognostic utility of best tumor response in metastatic renal cell carcinoma (mRCC) remains vague. Objective To define the prognostic relevance of the depth of remission in mRCC. Design, setting, and participants Pooled data from the Pfizer database for 2749 patients from phase 2 and 3 clinical trials in mRCC were analyzed. Tumor shrinkage was categorized according to the best percentage change in the sum of the largest diameter of target lesions. Outcome was computed using Kaplan-Meier curves and correlation was assessed via Cox regression, including a 6-mo landmark. Intervention Sunitinib, sorafenib, axitinib, temsirolimus, or temsirolimus and interferon-?. Outcome measurements and statistical analysis Categorized tumor shrinkage, overall survival (OS), progression free survival (PFS). Results and limitations Major tumor shrinkage of 60% or more occurred in approximately…(vermás)